Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments

Published:2019-03 Issue:2 Volume:2 Page:152-162
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Farolfi Andrea,Fendler Wolfgang,Iravani Amir,Haberkorn Uwe,Hicks Rodney,Herrmann Ken,Walz Jochen,Fanti Stefano

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference114 articles.

1. Theranostic concepts: more than just a fashion trend-introduction and overview;Herrmann;J Nucl Med,2017

2. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid;Seidlin;J Am Med Assoc,1946

3. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

4. A retrospective study of the time to clinical endpoints for advanced prostate cancer;Sharifi;BJU Int,2005

5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer;Cancers;2024-02-04

2. Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

3. Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices;Cancers;2023-06-10

4. Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study);Asia-Pacific Journal of Clinical Oncology;2023-03-31

5. Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020;European Journal of Nuclear Medicine and Molecular Imaging;2023-02-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3